Copyright
©The Author(s) 2017.
World J Cardiol. Feb 26, 2017; 9(2): 109-133
Published online Feb 26, 2017. doi: 10.4330/wjc.v9.i2.109
Published online Feb 26, 2017. doi: 10.4330/wjc.v9.i2.109
Ref. | Year | n | CMR time | Main findings | Follow-up |
El Aidi et al[32] | 2014 | 25497 | N/A | Meta analysis of prognostic value of CMR surrogate markers. LVEF was only IP for MACE (HR 1.05 per -5%) | N/A |
Husser et al[33] | 2012 | 304 | 7 d | LVEF was IP for MACE (HR 0.95 for each +1% LVEF) | 140 wk |
Eitel et al[34] | 2011 | 208 | 3 d | LVEF was IP for MACE (HR 0.95 for each +1% LVEF) | 18.5 mo |
Amabile et al[35] | 2010 | 114 | 6 d | LVEF was IP for MACE (HR 0.96 for each +1% LVEF) | 12 mo |
de Waha et al[36] | 2010 | 438 | 3 d | LVEF was IP for MACE (OR 1.63) and all-cause mortality (OR 2.51) | 19 mo |
Cochet et al[37] | 2009 | 127 | 3-7 d | LVEF of < 40% was IP for MACE (OR 1.20) | 12 mo |
Hombach et al[6] | 2005 | 110 | 6 d | LVEF was IP for 9 mo MACE (P = 0.006) | 225 d |
- Citation: Khan JN, McCann GP. Cardiovascular magnetic resonance imaging assessment of outcomes in acute myocardial infarction. World J Cardiol 2017; 9(2): 109-133
- URL: https://www.wjgnet.com/1949-8462/full/v9/i2/109.htm
- DOI: https://dx.doi.org/10.4330/wjc.v9.i2.109